User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

Interactions with Platform & by Email *

INTERACTIONS

Unique # Participated *

PARTICIPANTS

Responses Validated *

VALIDATIONS

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Quantitative Techniques & Analytics.....I-3
Product Definition and Scope of Study.....I-3
Bio-Pharmaceuticals.....I-3
Bio-Agriculture.....I-3
Bio-Industrial.....I-3
Bioinformatics.....I-3
Bio-Services.....I-3
  
   Recession and Foreign Exchange Rate Decelerate Industry Growth.....II-11$75
   Industry Emerges Strong Following Recession.....II-2
Brighter Prospects Ahead for the Indian Biotech Industry.....II-2
1$75
   SWOT Analysis.....II-31$75
   Diversity – Key Strength for the Industry.....II-4
Major Sectors in the Indian Biotechnology Industry.....II-4
1$75
   Government Support for Biotech Innovation – A Boost for the Industry.....II-5
Challenges Ahead.....II-5
1$75
   Concerted Efforts are On to Find a Way Out.....II-6
Major Industry-Specific Advantages of the Indian Biopharma Sector.....II-6
1$75
   Competition.....II-7
Table 1: Leading Biotech Companies in India by Revenues: 2009-10 (includes corresponding Graph/Chart).....II-7
1$350
   Table 2: Leading Domestic Biotech Companies in India by Revenues: 2009-10 (includes corresponding Graph/Chart).....II-8
Exports – A Major Market for Indian Biotech Industry.....II-8
1$350
   Table 3: Export Revenues of Indian Biotech Industry by Sector (2008-09 & 2009-10): Export Value in US$ Million for Bio-Pharma, Bio-Services, Bio-Agri, Bio-Industrial, and Bioinformatics (includes corresponding Graph/Chart).....II-9

Table 4: Biotechnology Industry Export Revenues as a Percentage Share of Total Segment Revenues: 2009-10 (includes corresponding Graph/Chart).....II-9
1$350
   Analysis by Region.....II-10
Western Region’s Domination Continues in Revenue Terms, Mumbai Moves to the
  Top.....II-10
Table 5: Leading States in the Indian Biotech Industry by Revenues: 2009-10 (includes corresponding Graph/Chart).....II-10
1$350
   Table 6: Leading Cities In the Indian Biotech Industry by Revenues: 2009-10 (includes corresponding Graph/Chart).....II-11
Karnataka Embarks on Further Growth Plans; Other Regions Join the League.....II-11
2$350
   Government Support to the Biotechnology Sector Surges.....II-13
Recognizing the Importance of Right Educational System.....II-13
1$75
   Need for a Streamlined Regulatory Process Continues.....II-14
Angel Funding – Still Eluding the Sector.....II-14
More Countries Look to India for Outsourcing.....II-14
China and India – Competing for Biotech Investments.....II-14
2$150
   Table 7: Indian Bio-Pharmaceuticals Market by Segment (2011): Percentage Share Breakdown for Vaccines, Diagnostics, Therapeutics, and Others (includes corresponding Graph/Chart).....II-16
Competitive Landscape of the Biopharma Sector.....II-16
1$350
   Table 8: Leading BioPharma Companies in India by Revenues: 2009-10 (includes corresponding Graph/Chart).....II-17
Market Analysis by Segment.....II-17
Vaccines.....II-17
Vaccines to Spearhead Growth in the Indian BioPharma Market.....II-17
1$350
   Demand for Vaccines to Surge.....II-18
India to Emerge as a Global Hub for Vaccines.....II-18
1$75
   Diagnostics.....II-19
India Diagnostics Market – An Overview.....II-19
Table 9: Leading Players in the Indian Diagnostics Market by Revenues: Market Share Breakdown of Revenues for Tulip, TransAsia Biomedical, Bayer, Span Diagnostics, and Others (2010) (includes corresponding Graph/Chart).....II-19
Indian Diagnostics Industry – Stifled with High Competition.....II-19
1$350
   Diagnostic Centers Expand Test Menu to Beat Competition.....II-20
Bio-Therapeutics - Going Strong.....II-20
Overseas Giants Dominate the Insulin Market.....II-20
Plasma Proteins – A Potential Growth Area.....II-20
1$75
   mAbs Gain Prominence in the Biopharma Industry.....II-21
Market Trends.....II-21
Climbing Up the Value Chain.....II-21
1$75
   Domestic Market to Provide Impetus to Bio-Pharma Industry Growth.....II-22
Biosimilars to Offer Tremendous Prospects for Indian Players.....II-22
1$75
   Table 10: Indian Market for Biosimilars by Drug Class (2009): Revenues for Insulin, EPO, Interferon, Streptokinase, and G-CSF (includes corresponding Graph/Chart).....II-23
Biopharmaceutical Pipeline Growth Continues.....II-23
r-DNA Biopharmaceuticals Cleared for Pre-Clinical Studies: 2009-10.....II-23
1$350
   Indian Firms Embrace Strategic Partnerships to Enter Biotech Industry.....II-241$75
   Indian Biopharma Market Luring Overseas Players.....II-251$75
   Indian Pharma Companies on a Co-Development Spree.....II-26
Vaccines Remain the Center of Focus in Indian BioPharma.....II-26
1$75
   Brighter Prospects Ahead in Original Drug Development.....II-27
Myriad Factors Drive Growth in the Indian BioPharma Sector.....II-27
1$75
   Pharma Companies Shift Focus to BioPharma.....II-281$75
   Indian Bio-Agriculture Industry – An Overview.....II-29
Select Biotech Crops in India Under Field Trials: 2008.....II-29
1$75
   Transgenic Crops Cleared for Limited Field Trials: 2009-10.....II-301$75
   India – A Leading Adopter of Biotech Crops Worldwide.....II-31
Bio-Agri Treads On A Fast-Track Growth Path.....II-31
Public and Private Sector Participation in Bio-Agri Research.....II-31
1$75
   Bt Cotton – A Major Success in India.....II-32
Indian Farmers Increasingly Embrace Bollgard II Cotton.....II-32
Monsanto And Mahyco to Battle Out Pink Bollworm Resistance in Bollgard – I.....II-32
1$75
   Move to Commercialize Bt Brinjal Draws Major Controversy.....II-33
Government Retreats, Imposes Moratorium on Launch of Bt Brinjal.....II-33
Moratorium on Bt Brinjal Launch, A Setback to the Industry?.....II-33
1$75
   Establishment of BRAI Also Faces the Heat of Opponents.....II-341$75
   Stark Criticism Compels India to Establish Transparent Administration of Biotech
  Procedures.....II-35
Bio-Diesel Market – Still in Infancy.....II-35
Bio-Fertilizers and Bio-Pesticides Market – An Overview.....II-35
1$75
   Competitive Scenario in the Bio-Agri Sector.....II-36
Table 11: Leading Bio-Agriculture Companies in India by Revenues: 2009-10 (includes corresponding Graph/Chart).....II-36
1$350
   Indian Bio-Industrial Sector – Fairly Concentrated.....II-37
Table 12: Leading Players in the Indian Bio-Industrial Sector (2009-10): Market Share as Percentage of Revenues for Novozymes, Advanced Enzyme Technologies, and Others (includes corresponding Graph/Chart).....II-37
1$350
   Indian BioInformatics Market Posts Sluggish Growth.....II-381$75
   Indian Bio-Services Market Bustling with Activity.....II-39
India – A Growing Hub for Clinical Trials.....II-39
1$75
   Competitive Scenario.....II-40
Table 13: Leading Biotechnology Services Companies in India By Revenues (2009-10) (includes corresponding Graph/Chart).....II-40
1$350
   Regulatory Evolution in the Country.....II-41
Department of Biotechnology.....II-41
Public Sector Undertakings under the DBT.....II-41
Autonomous Institutions operating under the DBT.....II-41
Roles and Responsibilities of DBT.....II-41
1$75
   Various Committees Operating Under the DBT and MoEF.....II-42
GEAC or the Genetic Engineering Approval Committee.....II-42
Review Committee on Genetic Manipulation.....II-42
Institutional Bio-Safety Committee.....II-42
1$75
   Recombinant DNA Advisory Committee.....II-43
Central Drugs Standard Control Organization.....II-43
Select Acts, guidelines and regulations that govern the biotechnology industry in
  India.....II-43
1$75
   Agencies Supporting and Financing Biotechnology Research in India.....II-44
New Regulatory Framework on the Horizon.....II-44
National Biotechnology Strategy.....II-44
1$75
   Biotech and Science Parks in the Country.....II-45
Select Biotech and Science Parks in India.....II-45
Major Research Institutes in India.....II-45
Select Key Research Institutes in India.....II-45
1$75
   Autonomous Biotechnology Institutes in India.....II-461$75
   Biotechnology.....II-47
A Peek into the History of Biotechnology.....II-47
Select Major Applications of Biotechnology.....II-47
1$75
   Medicine.....II-48
Pharmacogenomics.....II-48
Biopharmaceuticals.....II-48
Genetic Testing.....II-48
Gene Therapy.....II-48
1$75
   Cloning.....II-49
Agriculture.....II-49
Bioremediation and Biodegradation.....II-49
1$75
   Panacea Biotec to Introduce PacliALL.....II-50
Gene Logic Rolls Out ASCENTA System Version 4.0.....II-50
Bharat Biotech International Unveils HNVAC™ H1N1 Swine Flu Vaccine.....II-50
1$75
   Strand Scientific Intelligence Introduces Avadis NGS.....II-51
Dr Reddy’s Rolls Out Generic Darbepoetin Alfa Drug, Cresp®.....II-51
BD Biosciences and ReaMetrix Unveil New Reagents.....II-51
Serum Institute of India Rolls Out Nasovac H1N1 Vacccine in India.....II-51
1$75
   Ocimum Biosolutions Introduces Biotracker™.....II-52
Novo Nordisk Launches Antidiabetic Drug, Victoza in India.....II-52
Cadila Healthcare Launches Vaxiflu-S.....II-52
Ocimum Biosolutions Introduces qRT-PCR Services.....II-52
1$75
   Wockhardt Rolls Out Biotechnology Products.....II-53
Intas Biopharma Launches Borviz in India.....II-53
Bharat Biotech International Unveils COMVAC5® Vaccine.....II-53
1$75
   Piramal Healthcare to Change Name to Piramal Enterprises.....II-54
Bharat Biotech Commences Phase III Clinical Trial with THR-100.....II-54
Bayer Teams Up with Zydus for Joint Venture in India.....II-54
1$75
   Qiagen Establishes Qiagen India.....II-55
Ecron Acunova Expands Capacity at Mangalore Clinical Research Center.....II-55
IndianOil Inks MOU with LanzaTech.....II-55
Dow AgroSciences and GVK Biosciences Discover New Compound.....II-55
1$75
   Ecron Acunova Establishes Joint Venture CRO in Thailand.....II-56
Praj Industries Enters into Partnership with Qteros.....II-56
Mavens Biotech to Venture into Biotech Education.....II-56
1$75
   Aurobindo Pharma to Divest Stake in Its Chinese Subsidiary.....II-57
Abbott Acquires Formulation Business of Piramal Healthcare.....II-57
Evolvence India Life Sciences Takes Over Stake in Fermenta Biotech.....II-57
Strides Arcolab to Take Over 70% Stake in Inbiopro Solutions.....II-57
Rallis Acquires Majority Stake in Metahelix.....II-57
1$75
   Ocimum Secures US$8 Million Funding for Future Growth.....II-58
Dr. Reddy's to Purchase US Penicillin Facility and Product Rights from GSK.....II-58
Life Technologies to Take Over Labindia.....II-58
Biocon Enters into Strategic Global Agreement with Pfizer.....II-58
1$75
   Intas Biopharma to Ink Out-Licensing Deal with Japanese Firm.....II-59
Biocon Limited and CMI Enter into Immunology Research Collaboration.....II-59
Biocon Signs Contract with Teleradiology Solutions.....II-59
1$75
   Jubilant Organosys Changes Name to Jubilant Life Sciences.....II-60
Jubilant Inks CRAMS Deal with a US Firm.....II-60
MSCCC and Strand Life Sciences Ink MOU for Translational Cancer Research.....II-60
Lohmann Animal Health Enters into Joint Venture with Suguna.....II-60
1$75
   International Stem Cell Inks a Distribution Agreement with Sristi Biosciences.....II-61
BioServe Biotechnologies Receives NABL Accreditation for GMO Testing.....II-61
Indian Immunologicals to Develop Oral Cervical Cancer Vaccine.....II-61
Piramal Healthcare to Take Over the Assets of BioSyntech.....II-61
1$75
   Ocimum Biosolutions to Offer BioIT Consulting Services.....II-62
Zydus Obtains DCGI Clearance for Initiating Phase I Trials on Zyog1.....II-62
Krishidhan Establishes Subsidiary in Europe.....II-62
Biocon Limited Inks Supply Deal with Optimer Pharmaceuticals.....II-62
1$75
   Australia to Grant Research Funding to India.....II-63
Ocimum Biosolutions and Jivan Biologics Enter into Partnership.....II-63
Stempeutics Completes Phase I/II Study of Stemepucel-CLI Stem Cell Product.....II-63
Ranbaxy Enters into Alliance with Pfenex.....II-63
Syngene Collaborates with Endo Pharmaceuticals.....II-63
1$75
   Panacea Biotech Obtains Financial Assistance from DBT for Vaccine Development.....II-64
M. D. Anderson Cancer Center Selects Biotracker™ of Ocimum Biosolutions.....II-64
GVK Biosciences Establishes New Clinical Pharmacology Unit.....II-64
1$75
   Delta Embedded Solutions to merge with Bio-Analytical Technologies.....II-65
Clingene Seeks Alliance with SIRO Clinpharm.....II-65
Biocon Investments in Malaysian Biotech Market.....II-65
1$75
   Ranbaxy to Foray into Vaccines Market through Acquisition of Biovel's Assets.....II-66
Clinigene International Deploys PheedIt Solution of SAS.....II-66
Sanofi Takes Over Shantha Biotech.....II-66
1$75
   Bioseed Research India Inks Strategic Partnership Agreement with KeyGene.....II-67
PRAJ Partners with Novozymes.....II-67
Mylan sells stake in Concord Biotech.....II-67
Vibha Seeds Sets Up Seed Facility in Andhra Pradesh.....II-67
1$75
   Bayer Cropscience Inks Research Cooperation Agreement with GVK Biosciences.....II-68
Millipore Acquires Outstanding Stake of its Joint Venture in India.....II-68
Avesthagen Forms Joint Venture with Limagrain.....II-68
Indus Biotech Receives HIV Controller Status for IND02 from FDA.....II-68
1$75
   Bharat Biotech Commences Construction at Konark Knowledge Park in Orissa.....II-69
International Biotech Park to Forge International Alliances.....II-69
Merck Acquires Bangalore Genei.....II-69
Bharat Biotech Secures International Patents for Lysostaphin.....II-69
Genzyme Inks MoU with NIPER for Offering Biotechnology Fellowships.....II-69
1$75
   Biocon Enters into Agreement with Amylin Pharmaceuticals.....II-70
WHO and DCGI Direct Serum Institute of India to Focus on H1N1 Vaccine.....II-70
Acoris Research Enters into Strategic Partnership with c-LEcta.....II-70
Serum Institute of India to Expedite Vaccine Development.....II-70
1$75
   Sanofi Aventis Acquires Shantha Biotechnics.....II-71
Biocon Inks a Strategic Collaboration Agreement with Mylan.....II-71
Lonza to Invest in Genome Valley for Two Major Projects.....II-71
Bio-Rad Laboratories Integrates DiaMed Scientific Technologies in India.....II-71
1$75
   Syngene Enters into Alliance with DuPont Crop Protection.....II-72
Emami Biotech Limited and Calcutta Tramways Company Ink MoU.....II-72
TCG Lifesciences and Pfizer Extend Master Services Agreement.....II-72
1$75
   Biological E Commences Operations at New Campus.....II-73
Syngene Enters into Partnership with Sapient.....II-73
Intas Biopharmaceuticals Inks MoU with Government of Gujarat.....II-73
1$75
   Emami’s Bio-Diesel Obtains SGS Certification.....II-74
Ocimum Biosolutions Enters into Partnership with NuGEN.....II-74
1$75
   Biocon Collaborates with Abraxis to Introduce Abraxane in India.....II-75
Intas Biopharmaceuticals Takes Over BPD.....II-75
Bharat Biotech Completes Phase I/II Clinical Trials for 116E Oral Rotavirus
  Vaccine.....II-75
1$75
   Intas Biopharmaceuticals to Commercialize Gefitinib in India.....II-76
Avesthagen Inks LoI with ShigaMediX.....II-76
Ranbaxy Signs Collaborative Research Agreement with DBT.....II-76
Veeda Establishes Global Oncology Contract Research Organization.....II-76
1$75
   Avesthagen Signs Framework Agreement with DuBiotech.....II-77
Biocon Buys Majority Stake in German Company.....II-77
Monsanto India to Sell Butachlor & Alachlor Businesses to Sinochem
  International.....II-77
Biocon Signs Strategic Partnership Agreement with IATRICa.....II-77
1$75
   Intas Pharmaceuticals to Sell Biotechnology Products in GCC.....II-781$75
   Advanced Enzymes Technologies Ltd......II-79
Ajeet Seeds Ltd......II-79
Anthem BioSciences Pvt. Ltd......II-79
1$75
   Bharat Biotech International Limited.....II-80
Bharat Serums and Vaccines Ltd......II-80
1$75
   Biocon Limited.....II-81
Syngene International Limited.....II-81
1$75
   Dr. Reddy's Laboratories Ltd.....II-82
Ecron Acunova.....II-82
1$75
   Eli Lilly and Company (India) Pvt. Ltd......II-83
GlaxoSmithKline Pharmaceuticals Ltd......II-83
Indian Immunologicals Ltd......II-83
1$75
   Jubilant Life Sciences Limited.....II-84
Krishidhan Seeds Private Limited.....II-84
1$75
   Lambda Therapeutic Research Ltd......II-85
Mahyco.....II-85
1$75
   Max Neeman.....II-86
Monsanto.....II-86
Novo Nordisk India Pvt. Ltd......II-86
Novozymes South Asia Pvt. Ltd......II-86
1$75
   Nuziveedu Seeds Pvt. Ltd......II-87
Ocimum Biosolutions Ltd......II-87
1$75
   Panacea Biotec Ltd......II-88
Piramal Healthcare Limited.....II-88
1$75
   Quintiles India.....II-89
Rasi Seeds (P) Ltd......II-89
1$75
   Reliance Life Sciences.....II-90
Serum Institute of India Ltd......II-90
1$75
   Shantha Biotechnics Limited.....II-91
SIRO Clinpharm.....II-91
Strand Life Sciences.....II-91
1$75
   Veeda Clinical Research Limited.....II-92
Vimta Labs Limited.....II-92
1$75
   Table 14: Indian Recent Past, Current & Future Analysis for Biotechnology Industry by Sector – Bio-Pharmaceuticals, Bio-Agriculture, Bio-Industrial, Bioinformatics, and Bio-Services Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-931$350
   Table 15: Indian Historic Review for Biotechnology Industry by Sector– Bio-Pharmaceuticals, Bio-Agriculture, Bio-Industrial, Bioinformatics, and Bio-Services Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-941$350
   Table 16: Indian 15-Year Perspective for Biotechnology Industry by Sector – Percentage Breakdown of Dollar Sales for Bio-Pharmaceuticals, Bio-Agriculture, Bio-Industrial, Bioinformatics, and Bio-Services Markets for Years 2003, 2011 and 2017 (includes corresponding Graph/Chart).....II-951$350
   Table 17: Indian Recent Past, Current & Future Analysis for Bio-Pharmaceuticals by Segment – Vaccines, Diagnostics, Therapeutics, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-961$350
   Table 18: Indian Historic Review for Bio-Pharmaceuticals by Segment – Vaccines, Diagnostics, Therapeutics, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-971$350
   Table 19: Indian 15-Year Perspective for Bio-Pharmaceuticals by Segment – Percentage Breakdown of Dollar Sales for Vaccines, Diagnostics, Therapeutics, and Others Markets for Years 2003, 2011 and 2017 (includes corresponding Graph/Chart).....II-981$350
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com